A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults.

NCT02017899 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Shigellosis

Interventions

BIOLOGICAL: S. sonnei 1790GAHB
BIOLOGICAL: Placebo

Sponsor

GSK Vaccines Institute For Global Health S.r.l.